secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2026-08-04T20:03:32+00:00
Accession:  0001628280-26-052527
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira Q2 revenue $192.4M (+6% YoY); divests iovera° to Zimmer Biomet for up to $140M
--------------------------------------------------------------------------------

- Q2 total revenue $192.4M (+6% YoY); GAAP net income $4.7M ($0.12 EPS) vs net loss of $4.8M in Q2 2025.
- EXPAREL net sales $147.8M (+3% YoY); ZILRETTA $32.6M (+4%); iovera $6.8M (+22%).
- Completed divestiture of iovera° to Zimmer Biomet for up to $140M ($70M upfront + milestones); closed July 31, 2026.
- UnitedHealthcare now provides separate reimbursement for EXPAREL, covering ~40M lives.
- Updated FY2026 total revenue guidance to $735M-$760M (from $745M-$770M) reflecting iovera divestiture.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000162828026052527/0001628280-26-052527-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000162828026052527/pcrx-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-052527

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer